Free Trial
NASDAQ:BNTX

BioNTech (BNTX) Stock Price, News & Analysis

BioNTech logo
$98.84 +0.57 (+0.58%)
As of 10:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About BioNTech Stock (NASDAQ:BNTX)

Advanced

Key Stats

Today's Range
$97.96
$98.93
50-Day Range
$96.22
$115.31
52-Week Range
$81.20
$129.27
Volume
121,602 shs
Average Volume
967,385 shs
Market Capitalization
$23.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$134.56
Consensus Rating
Moderate Buy

Company Overview

BioNTech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

BNTX MarketRank™: 

BioNTech scored higher than 54% of companies evaluated by MarketBeat, and ranked 474th out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside Potential

    BioNTech has a consensus price target of $134.56, representing about 36.3% upside from its current price of $98.75.

  • Amount of Analyst Coverage

    BioNTech has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BioNTech's stock forecast and price target.
  • Earnings Growth

    Earnings for BioNTech are expected to decrease in the coming year, from ($3.88) to ($4.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioNTech is -61.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioNTech is -61.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioNTech has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about BioNTech's valuation and earnings.
  • Percentage of Shares Shorted

    2.54% of the float of BioNTech has been sold short.
  • Short Interest Ratio / Days to Cover

    BioNTech has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in BioNTech has recently decreased by 4.75%, indicating that investor sentiment is improving.
  • Dividend Yield

    BioNTech does not currently pay a dividend.

  • Dividend Growth

    BioNTech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.54% of the float of BioNTech has been sold short.
  • Short Interest Ratio / Days to Cover

    BioNTech has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in BioNTech has recently decreased by 4.75%, indicating that investor sentiment is improving.
  • News Sentiment

    BioNTech has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for BioNTech this week, compared to 12 articles on an average week.
  • Search Interest

    52 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 271% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added BioNTech to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioNTech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 15.52% of the stock of BioNTech is held by institutions.

  • Read more about BioNTech's insider trading history.
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BNTX Stock News Headlines

JPMorgan Chase & Co. Raises BioNTech (NASDAQ:BNTX) Price Target to $121.00
IRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.tc pixel
See More Headlines

BNTX Stock Analysis - Frequently Asked Questions

BioNTech's stock was trading at $113.95 at the beginning of 2025. Since then, BNTX stock has decreased by 13.3% and is now trading at $98.7450.

BioNTech SE Sponsored ADR (NASDAQ:BNTX) issued its quarterly earnings results on Monday, August, 4th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($1.41) by $0.19. The business's revenue was up 102.6% on a year-over-year basis.
Read the conference call transcript
.

BioNTech subsidiaries include Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and more.

BioNTech (BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

Top institutional shareholders of BioNTech include Flossbach Von Storch SE (1.76%), Primecap Management Co. CA (1.66%), Temasek Holdings Private Ltd (0.63%) and BNP Paribas Financial Markets (0.53%).

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/04/2025
Today
9/24/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BNTX
CIK
1776985
Employees
6,772
Year Founded
2008

Price Target and Rating

High Price Target
$171.44
Low Price Target
$110.00
Potential Upside/Downside
+36.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.60)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$719.92 million
Net Margins
-12.20%
Pretax Margin
-13.81%
Return on Equity
-1.84%
Return on Assets
-1.59%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
8.61
Quick Ratio
8.48

Sales & Book Value

Annual Sales
$2.98 billion
Price / Sales
7.93
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$87.61 per share
Price / Book
1.12

Miscellaneous

Outstanding Shares
240,400,000
Free Float
194,242,000
Market Cap
$23.62 billion
Optionable
Optionable
Beta
1.39

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:BNTX) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners